DNA X delays Q2 10-Q filing, cites convertible debt and consolidation accounting complexities

• DNA X filed a Form 12b-25 to delay its quarterly report for the period ended June 30, 2026.
• Filing delay tied to accounting for sale of convertible debt, variable interest entities under ASC 810, consolidation of DNA X, LLC.
• Put option termination on May 27, 2026 triggered a conclusion that DNA X, LLC is fully controlled, requiring GAAP consolidation.
• Quarterly report expected on or before the fifth calendar day after the original due date.
• Net loss from continuing operations expected near $1 million, versus about $1.9 million a year earlier.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DNA X Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038320), on August 14, 2026, and is solely responsible for the information contained therein.